Trials / Conditions / DS Stage I Plasma Cell Myeloma

DS Stage I Plasma Cell Myeloma

10 registered clinical trials studyying DS Stage I Plasma Cell Myeloma.

Status	Trial	Sponsor	Phase
Completed	Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multip NCT01936090	Mayo Clinic	Phase 1
Completed	Carfilzomib and Melphalan Before Stem Cell Transplant in Treating Patients With Multiple Myeloma NCT01842308	Mayo Clinic	Phase 1 / Phase 2
Active Not Recruiting	S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly D NCT01668719	SWOG Cancer Research Network	Phase 1 / Phase 2
Completed	Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple NCT01605032	Albert Einstein College of Medicine	Phase 2
Completed	Vismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple NCT01330173	National Cancer Institute (NCI)	Phase 1
Withdrawn	RO4929097 After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma NCT01251172	National Cancer Institute (NCI)	Phase 2
Completed	Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple My NCT00869206	Alliance for Clinical Trials in Oncology	Phase 3
Completed	Bortezomib and Vorinostat in Treating Patients With Multiple Myeloma Who Have Undergone Autologous Stem Cell T NCT00839956	Fred Hutchinson Cancer Center	Phase 2
Completed	Lenalidomide, Dexamethasone, and Clarithromycin in Treating Patients Who Have Undergone Stem Cell Transplant f NCT00445692	Fred Hutchinson Cancer Center	Phase 2
Completed	Bortezomib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Previously Untreated Sy NCT00088855	National Cancer Institute (NCI)	Phase 2